Teva Pharmaceutical Industries has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. The separation is planned to take effect July 1, 2018 subject to receipt of applicable regulatory approvals. No significant (material) net financial transfer between Teva and P&G will result from the dissolution.
— Businesswire
Teva is based in Israel but has Indian and Chinese subsidiaries and operations.
Platinum Partners advised
Goodwin Procter acted as
Cyril Amarchand Mangaldas represented
Primary jurisdiction of deal:
2018-10-08
Deal value: Confidential
This deal report is based on a firm's press release and may be only partially complete. Some firms or names of advisers may be therefore be missing.